Five named by the commission. One of the five returned a null at Ramadan exposure. That null is published as prominently as the positives.
D1. Lithium toxicity
| Field | Content |
|---|---|
| Grade | B+ (prospective observational, 250 patients) |
| Verdict at intermittent exposure | NULL. No significant change in serum lithium or renal function. |
| Identifier | PMID 40366534, PMC12078900, DOI 10.1186/s40345-025-00378-7 |
| Citation | Abouzed M, Altuhayni AS, Alshammari SR, Almuqahhwi MS, Elgernas M, Almazyadi A, Alghuraymil AA, Ibrahim Y, Alenezy A. "Short-term and long-term effects of Muslim fasting on lithium pharmacokinetics and renal function in bipolar disorder: a prospective observational study." International Journal of Bipolar Disorders 2025 May 14;13:17. |
Mechanism as classically stated: lithium is cleared by the kidney and reabsorbed with sodium in the proximal tubule; volume depletion raises proximal sodium and lithium reabsorption, so serum lithium rises toward the toxic range. That mechanism is not a measurement and is marked as mechanism, not as a finding in this study.
MEASURED, serum lithium, fasting versus non-fasting (mean ± SD; the paper does not state units in Table 2):
- Baseline 0.85 ± 0.03 vs 0.84 ± 0.02, p = 0.45
- Mid-Ramadan 0.81 ± 0.02 vs 0.84 ± 0.03, p = 0.052
- One month post 0.82 ± 0.02 vs 0.85 ± 0.03, p = 0.072
- Three months post 0.81 ± 0.02 vs 0.83 ± 0.02, p = 0.065
- Cohen's d = 0.25
- Mixed-effects model: no significant fasting-by-time interaction
MEASURED, renal: creatinine p = 0.378 to 0.624 across time points; eGFR p = 0.65 to 0.80. Baseline creatinine 0.88 ± 0.09 vs 0.87 ± 0.08 mg/dL; eGFR 92.5 ± 14.8 vs 93.0 ± 13.5 mL/min. Mid-Ramadan creatinine 0.90 ± 0.10 vs 0.89 ± 0.09 mg/dL; eGFR 92.0 ± 14.5 vs 92.5 ± 13.2 mL/min.
MEASURED, sample: n = 250 analyzed (fasting 131, non-fasting 119). Of 286 who agreed, 36 were lost to follow-up. Sampling at baseline, mid-Ramadan, one month and three months after.
READ, verbatim: > "Ramadan fasting did not significantly alter serum lithium levels, renal function, or electrolyte balance"
> "fasting during Ramadan can be safely practiced by patients with bipolar disorder receiving lithium therapy"
MEASURED gap: no lithium toxicity event counts are reported. Chi-square tests on adverse events showed no significant between-group differences (p > 0.05).
Direction of the mid-Ramadan result recorded exactly: lithium went down in fasters, not up, and the difference approached but did not cross significance at p = 0.052. This cuts against the classical mechanism at a 14-hour exposure. It says nothing about a continuous multi-day dry fast, where no lithium study exists in any language.
D2. NSAID nephrotoxicity, with RAS inhibitors and diuretics
| Field | Content |
|---|---|
| Grade | B+ (nationwide cohort plus case-crossover). Not graded A: it is a cohort study, not an RCT or meta-analysis. |
| Verdict | POSITIVE and quantified. Fasting was not part of this study. |
| Identifier | PMID 40826437, PMC12359997, DOI 10.1186/s40780-025-00485-8 |
| Citation | "NSAID-Induced acute kidney injury risk in patients on renin-angiotensin system inhibitors and diuretics: nationwide cohort study." Journal of Pharmaceutical Health Care and Sciences, 2025. |
MEASURED:
| Group | n | AKI incidence per 1,000 person-years | Effect estimate (95% CI) | p |
|---|---|---|---|---|
| Dual therapy: RAS inhibitors + diuretics, no NSAIDs | not separately reported | 9.6 (9.0 to 10.0) | reference | |
| Triple therapy: RAS inhibitors + diuretics + NSAIDs | 41,904 | 20.0 (14.8 to 25.6), 54 AKI cases | IRR 2.08 (1.58 to 2.74) vs dual | not reported |
| NSAID use, case-crossover within RASI + diuretic users | 2,909 AKI patients, 5,818 control periods | not reported | aOR 1.44 (1.17 to 1.78) | < 0.001 |
READ, verbatim: > "Case-crossover analysis showed an aOR of 1.44 [95% CI: 1.17–1.78] for AKI associated with NSAID use."
> "TW with the addition of NSAIDs in patients receiving RASIs and diuretics significantly increased the incidence of AKI"
Stated plainly. The study reports odds ratios and incidence rate ratios, not hazard ratios, and the NSAID-alone estimate comes from a case-crossover analysis of patients already on RAS inhibitors and diuretics, not a direct comparison with dual therapy.
Mechanism. NSAIDs block prostaglandin-mediated afferent arteriolar vasodilation; RAS inhibitors block efferent arteriolar constriction; diuretics reduce circulating volume. All three together remove the kidney's compensation for low perfusion.
INFERRED (one hop, marked as inference, not measurement). Hop 1: triple therapy doubled AKI incidence to 20.0 per 1,000 person-years in a euvolemic outpatient population (MEASURED). A dry fast removes fluid intake, which is the same direction of insult as the diuretic arm. No study has measured the triple-whammy combination during a dry fast, so the size of that combined risk is not measured and no number is given for it here.
Governing text. NHS NEL, READ verbatim: "Drugs including diuretics may contribute to dehydration/acute kidney injury (AKI)." For RAS inhibitors: patients "should not stop taking these medications unless they are specifically asked to do so by their clinician."
D3. SGLT2 inhibitors and euglycemic ketoacidosis
| Field | Content |
|---|---|
| Grade | C (single case report) |
| Verdict | DOCUMENTED in a fasting context. One case. |
| Identifier | PMID 35346357, PMC8962204, DOI 10.1186/s13256-022-03347-1 |
| Citation | "Euglycemic diabetic ketoacidosis induced by sodium-glucose cotransporter 2 inhibitor in the setting of prolonged fasting: a case report." Journal of Medical Case Reports 2022 Mar 29;16:138. |
MEASURED:
- 51-year-old male with type 2 diabetes
- Dapagliflozin 5 mg added to metformin 1000 mg daily, 12 weeks before presentation
- Fast: Ramadan, about 14 hours daily for 30 days, food and drink
- Glucose at presentation 13.5 mmol/L (243 mg/dL), which is why it is euglycemic DKA and not classical DKA
- Bicarbonate 4 mmol/L (venous blood gas)
- pH 6.92 (venous blood gas)
- Anion gap 30 mEq/L
- Urine positive for ketones and glucose
READ, verbatim: > "He observed Ramadan month by fasting an average of 14 hours daily for 30 days."
> "Fasting from food and drinks lasted daily for approximately 14 hours daily."
> "The venous blood gas results showed severe metabolic acidosis with a high anion gap, pH of 6.9"
> "Physicians should have a high level of suspicion for EDKA if the patient is on a SGLT2 inhibitor."
MEASURED gap: beta-hydroxybutyrate was not reported. Only positive urine ketones.
This is the most important single row in Section D and the reason is the glucose. The patient presented with a glucose of 243 mg/dL and a pH of 6.92. A normal-looking glucose does not rule out life-threatening ketoacidosis on an SGLT2 inhibitor during a fast. That is the documented hazard, in one case, at a 14-hour exposure with overnight rehydration.
Governing text. NHS NEL, READ verbatim: SGLT2 inhibitors are "ideally, don't start within one month of or during Ramadan. If stable on it, do not stop it." IDF-DAR does not name SGLT2 inhibitors anywhere in its risk-scoring table (see C0).
Open debt, stated: a systematic review of SGLT2 inhibitor use during Ramadan exists (Thieme, DOI 10.1055/s-0044-1791484) and a meta-analysis exists at PMC12897491. I did not open either: Thieme returned an automated-request block and PMC returned reCAPTCHA. No pooled DKA rate during Ramadan is reported in this register because none was obtained.
D4. Diuretics
| Field | Content |
|---|---|
| Grade | NG for the governing text. B+ for the quantified nephrotoxicity, but measured without fasting (see D2). |
| Verdict | No study measuring diuretic users during a dry fast was located in any language. Denominator: 0. |
READ, NHS North East London, verbatim: > "Drugs including diuretics may contribute to dehydration/acute kidney injury (AKI)."
Patients on diuretics "may need to review with a clinician to consider dose changes/alternatives."
MEASURED, from D2: adding NSAIDs on top of RAS inhibitors plus diuretics took AKI from 9.6 to 20.0 per 1,000 person-years, IRR 2.08 (1.58 to 2.74). In that cohort the diuretic was part of the baseline exposure, not the variable.
Mechanism, marked as mechanism: loop and thiazide diuretics reduce circulating volume and increase renal sodium and water loss. A dry fast removes intake while the drug continues removing output. Nobody has measured that combination. The gap is stated rather than filled.
D5. Anticoagulants
| Field | Content |
|---|---|
| Grade | A (systematic review and meta-analysis, 5 studies, 446 patients) |
| Verdict | Mostly null during the fast. One significant signal, and it is AFTER Ramadan, not during it. |
| Identifier | DOI 10.1007/s00228-022-03281-7. PMID not shown on the page I opened. |
| Citation | Rabea EM, Abbas KS, Awad DM, Elgoweini NH, El-Sakka AA, Mahmoud NH, Abdelazeem B. "Does Ramadan fasting affect the therapeutic and clinical outcomes of warfarin? A systematic review and meta-analysis." European Journal of Clinical Pharmacology 2022;78(5):755-763. Published 18 Feb 2022. |
MEASURED:
- 5 studies, 446 patients, each serving as their own control
- INR during versus pre-Ramadan: MD 0.08 (95% CI −0.00 to 0.15), p = 0.06, not significant
- INR post versus pre-Ramadan: MD −0.00 (95% CI −0.14 to 0.14), p = 1.00, not significant
- Supratherapeutic INR, post versus pre-Ramadan: RR 1.69 (95% CI 1.22 to 2.33), p = 0.001. The only significant finding.
- Supratherapeutic INR during versus pre- or post-Ramadan: not significant; the page does not give the exact estimates
- Time in therapeutic range: no significant difference during, before or after; no numeric values given on the page
READ, verbatim: > "There was only a significant increase in the risk ratio of supratherapeutic INR when comparing post-Ramadan vs. pre-Ramadan"
> "Ramadan fasting did not affect INR level, TTR, or the number of patients within the therapeutic range"
The authors conclude that INR monitoring and warfarin dose adjustment are recommended after Ramadan, because supratherapeutic INR was more likely post-Ramadan than pre-Ramadan.
MEASURED gap: bleeding and thromboembolic event counts were not reported in the content I opened.
Governing text. NHS NEL, on direct oral anticoagulants, READ verbatim: "avoid >12 hours between taking twice a day anticoagulant", because of the risk of not achieving 24 hours of anticoagulation.
Recorded exactly as found. The anticoagulation hazard that reached statistical significance is a post-fast INR overshoot, not a within-fast one. That is the opposite of the intuitive story and it is published here unaltered.
dryfasting.com has been published since 2014. This evidence record was compiled on 22 November 2026. Every row names the fasting modality the study actually ran, the system it was measured in and the grade. Where no source carries a DOI or PMID the row says so rather than supplying one. Nothing is sold on this site.